Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
Liliana Antunes, Madelyn Yiseth Rojas Castro, Marcos Iglesias, Iván Martínez‐Baz, Isabel Leroux‐Roels, Maria‐Louise Borg, Beatrix Oroszi, Margaret Fitzgerald, Ralf Dürrwald, Ligita Jančorienė, Ausenda Machado, Goranka Petrović, Mihaela Lazăr, Lenka Součková, Sabrina Bacci, Jennifer Howard, Nuno Verdasca, Luca Basile, Jesús Castilla, Silke Ternest, Aušra Džiugytė, Gergő Túri, Róisín Duffy, Carolin Hackmann, Monika Kuliešė, Verónica Gomez, Zvjezdana Lovrić Makarić, Alexandru Marin, Petr Husa, Nathalie Nicolay, Angela Rose, VEBIS SARI VE network team
Abstract
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.